Evidence map›Paper›PMID 39423857›Full record

ArticleJournal of neuropathology and experimental neurology2025

Multidimensional analysis of matched primary and recurrent glioblastoma identifies contributors to tumor recurrence influencing time to relapse.

Tala Shekarian, Marie-Françoise Ritz, Sabrina Hogan, Tomás A Martins, Philip Schmassmann, Alexandra Gerber, Julien Roux, Deniz Kaymak, Célia Durano, Bettina Burger and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuropathology and experimental neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tala ShekarianBrain Tumor Immunotherapy and Biology Laboratory, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Marie-Françoise RitzBrain Tumor Immunotherapy and Biology Laboratory, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.ORCID 0000-0002-5650-9987
Sabrina HoganBrain Tumor Immunotherapy and Biology Laboratory, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Tomás A MartinsBrain Tumor Immunotherapy and Biology Laboratory, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Philip SchmassmannBrain Tumor Immunotherapy and Biology Laboratory, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Alexandra GerberBrain Tumor Immunotherapy and Biology Laboratory, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Julien RouxBioinformatics Core Facility, Department of Biomedicine, University of Basel, Basel, Switzerland.
Deniz KaymakBrain Tumor Immunotherapy and Biology Laboratory, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Célia DuranoBrain Tumor Immunotherapy and Biology Laboratory, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Bettina BurgerDermatology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Matthias MatterInstitute of Pathology, University Hospital Basel, Basel, Switzerland.
Gregor HutterBrain Tumor Immunotherapy and Biology Laboratory, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.

Funding

Department of Surgery, University Hospital BaselKrebsliga beider Basel 5072-02-2020ProPatient ForschungsstiftungSwiss Cancer Research KFS-4382-02-2018Swiss National Science Foundation Professorial PP00P3_176974Swiss National Science Foundation Professorial Fellowship PP00P3_176974The Brain Tumour Charity Foundation GN-000562The Swiss Life Jubiläumsstiftung 1138 and 1196University Hospital Basel
6 · The paper itself

Abstract

Glioblastoma (GBM) is a lethal brain tumor without effective treatment options. This study aimed to characterize longitudinal tumor changes in order to find potentially actionable targets to prevent GBM relapse. We extracted RNA and proteins from fresh frozen tumor samples from patient-matched IDHwt WHO grade 4 primary (pGBM) and recurrent (rGBM) tumors for transcriptomics and proteomics analysis. A tissue microarray containing paired tumor samples was processed for spatial transcriptomics analysis. Differentially expressed genes and proteins between pGBM and rGBM were involved in synapse development and myelination. By categorizing patients into short (STTR) and long (LTTR) time-to-lapse, we identified genes/proteins whose expression levels positively or negatively correlated with TTR. In rGBM, expressions of Fcγ receptors (FCGRs) and complement system genes were negatively correlated with TTR, whereas expression of genes involved in DNA methylation was positively correlated with TTR. Spatial transcriptomics of the tumor cells showed enrichment of oligodendrocytes in rGBM. Besides, we observed changes in the myeloid compartment such as a switch from quiescent to activated microglia and an enrichment in B and T cells in rGBM with STTR. Our results uncover a role for activated microglia/macrophages in GBM recurrence and suggest that interfering with these cells may hinder GBM relapse.

Indexed as

Brain NeoplasmsGlioblastomaNeoplasm Recurrence, LocalAdultAgedFemaleHumansMaleMiddle Agedglioblastoma recurrencemicroglia transcriptomicproteomicspatial transcriptomic

Identifiers

PMID39423857
PMCPMC11659594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.